US Moderna vaccine could prevent 94.5% of people from getting Covid

16 November 2020, 12:02 | Updated: 16 November 2020, 12:23

British scientists have hailed the "tremendously exciting" news that a US coronavirus vaccine may prevent 94.5% of people from getting Covid-19.

Interim data from the US firm Moderna suggests its vaccine is highly effective in preventing people getting ill and also works across all age groups, including the elderly.

The UK has not placed an order for the vaccine - which works in a similar way to Pfizer's - but a Government spokesperson told LBC they "are in advanced talks with Moderna on a Covid-19 vaccine."

Read more: Janssen Covid vaccine: Major trial launches in UK

Read more: Covid testing megalabs set to more than double capacity

Earlier on Monday, Health Secretary Matt Hancock told LBC's Nick Ferrari that taking the Covid-19 vaccine is "much less worse than getting the virus".

The Health Secretary said that getting vaccine "protects you but also all those around you and your loved ones" and dismissed anti-vaccination campaigners as people in the extreme minority.

"It wouldn't be allowed if it weren't safe and that's why we've been doing these trials and why we haven't yet rolled out the vaccine, because we are absolutely determined that it will be safe," he added.

Scientists said the news bodes well for other Covid-19 vaccines, with the one for Oxford University and UK pharmaceutical giant AstraZeneca due to report in the coming days or weeks.

Moderna intends to submit an application for an Emergency Use Authorisation with the US Food and Drug Administration shortly and will submit further data on the vaccine's effectiveness and safety.

The firm's final-stage clinical trial is ongoing and includes more than 30,000 people in the US.

The interim analysis included 95 participants with confirmed cases of Covid-19, of which 90 had received the placebo and five the active vaccine.

The 95 cases included 15 older adults - aged 65 and over. This included 20 people who were not white - including 12 of whom were from Hispanic or Latino/a backgrounds, four African Americans, three Asian Americans and one who was multiracial.

Severe cases of coronavirus were also examined, including 11 severe cases in the first interim analysis.

All 11 cases occurred in the placebo group and none in the group which had received the vaccine, known currently as mRNA-1273.

Moderna said its available safety data does not indicate any significant safety concerns.

The vaccine was generally safe and well tolerated, and the majority of adverse events were mild or moderate in severity, it said.

Severe events after the first dose included injection site pain and after the second dose included fatigue, myalgia (muscle pain), arthralgia (joint pain), headache, pain, and redness at the injection site.

But these effects of the injection were generally short-lived, Moderna said.

The 94.5% efficacy from this analysis could drop as further results from the clinical trial are announced.

Stephane Bancel, chief executive officer of Moderna, said: "This is a pivotal moment in the development of our Covid-19 vaccine candidate.

"Since early January, we have chased this virus with the intent to protect as many people around the world as possible.

"All along, we have known that each day matters.

"This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent Covis-19 disease, including severe disease."

The news came after it was revealed the UK is set to become the first country to run final-stage trials of a Covid-19 vaccine being developed by a company owned by Johnson and Johnson.

For the two-dose Janssen study, researchers are aiming to recruit around 6,000 UK participants - from a total of 30,000 people globally - at 17 sites across the country.

It will be the third vaccine to be trialled in the UK, along with the Oxford/AstraZeneca candidate and another from US biotech company Novavax.

The UK has managed to secure 30 million doses of the Janssen vaccine if the trial is successful.

The jab has already undergone phase one and two trials, and analysis of the single-dose study suggests the vaccine induces a robust immune response and is generally well-tolerated.

Recruitment into the study will complete in March 2021 and the trial will last for 12 months.

So far around 25,000 people in the UK have participated in vaccine trials, and more than 310,000 have signed up to be contacted indicated their willingness to take part in clinical studies by signing up to the NHS vaccine research registry.

Following the Moderna announcement, Peter Openshaw, professor of experimental medicine at Imperial College London, said: "This news from Moderna is tremendously exciting and considerably boosts optimism that we will have a choice of good vaccines in the next few months.

"First we heard 90% efficacy from Pfizer and BioNTech, then the Russians said 92% and now Moderna says 94.5%.

"This latest press release is based on a study of 30,000 US adults, including many high-risk or elderly persons.

"This gives us confidence that the results are relevant in the people who are most at risk of Covid-19 and in most need of the vaccines.

"Moderna have also announced that the vaccine can be kept in a conventional freezer (-20C) for up to six months, and that once thawed the vaccine can be kept for up to 30 days at standard refrigerator (2 to 8C). This makes the vaccine much easier to deliver."

Stephen Evans, professor of pharmacoepidemiology at the London School of Hygiene and Tropical Medicine, said: "This announcement from Moderna is a further encouragement that vaccines will be found to not only have an acceptable efficacy, but an efficacy that is much greater than we had anticipated."